Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia

Annals of Pharmacotherapy

Volumn 31, Issue 1, 1997, Pages 15-22

  Sheffield, Reinée E ^a   Sullivan, Sean D ^a   Saltiel, Emmanuel ^b   Nishimura, Lyn ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c Drug Utiliz Eval Dept of Pharmacy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG COST; DRUG RESPONSE; HEALTH CARE COST; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031027055     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100101     Document Type: Article

References (58)

1. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a Phase III multicenter clinical trial. Ann Intern Med 1989;111:992-1000.
2. Bunn H. Recombinant human erythropoietin therapy in cancer patients. J Clin Oncol 1990;8:949-51.
3. Fischl M, Galpin S, Levine JE, Levine JD, Groopman JE, Henry DH, et al. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 1990;322:1488-93.
4. Pincus T, Olsen NJ, Russell J, Wolfe F, Harris RE, Schnitzer TJ, et al. Multi-center study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med 1990;89:161-8.
5. Harris DCH, Chapman D, Stewart JH, Lawrence S, Roger SD. Low dose erythropoietin in maintenance haemodialysis: improvement in quality of life and reduction in true cost of haemodialysis. Aust N Z J Med 1991;21:693-700.
6. Stevens ME, Summerfield GP, Hall AA, Beck CA, Harding AJ, Cove-Smith JR, et al. Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease. BMJ 1992;304:474-7.
7. Sheingold S, Churchill D, Muirhead N, Laupacis A, Labelle R, Goeree R. The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in Canada. Soc Sci Med 1992;34:983-91.
8. Moran LJ, Carey P, Johnson CA. Cost-effectiveness of epoetin alfa therapy for anemia of end-stage renal disease. Am J Hosp Pharm 1992;49: 1451-4.
9. Weinstein MC, Fineberg HV. Clinical decision analysis. Philadelphia: WB Saunders Co., 1980:12-36.
10. Petitti DB. Meta-analysis, decision analysis and cost-effectiveness analysis: methods for quantitative synthesis in Medicare. New York: Oxford University Press, 1994:20.
11. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993;29A(suppl 2):S2-8.
12. Case DC, Bukowdi RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993;85:801-6.
13. Ludwig H, Fritz E, Kotzmann H, Hocker P, Gisslinger H, Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990;322:1693-9.
14. Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 1994;73:2535-42.
15. Ludwig H, Fritz E, Leitgeb C, Krainer M, Kuhrer I, Sagaster P, et al. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol 1993;4:161-7.
16. Miller CB, Platanias LC, Mills SR, Zahurak ML, Ratain MJ, Ettinger DS, et al. Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst 1992;84:98-103.
17. Markman M, Reichman B, Hakes T, Rubin S, Jones W, Lewis JL, et al. The use of recombinant human erythropoietin to prevent carboplatin-induced anemia. Gynecol Oncol 1993;49:172-6.
18. Platanias LC, Miller CB, Mick R, Hart RD, Ozer H, McEvilly JM, et al. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol 1991;9:2021-6.
19. Oster W, Herrmann F, Gamm H, Zeile G, Lindermann A, Muller G, et al. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol 1990;8:956-62.
20. Walker R. Transfusion risks. Am J Clin Pathol 1987;88:374-8.
21. Robert NJ, Beveridge RA. Management of recurrent breast cancer. Obstet Gynecol Clin North Am 1994;21:709-19.
22. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992;327:1434- 41.
23. Mohandas D, Aledort L. Transfusion requirements, risks, and costs for patients with malignancy. Transfusion 1995;35:427-30.
24. Etchason J, Petz L, Keeler E, Calhoun L, Kleinman S, Snider C, et al. The cost effectiveness of preoperative autologous blood donations. N Engl J Med 1995;332:719-24.
25. Healy JC, Frankfurter SA, Graves BK, Reddy RL, Beck JR. Preoperative autologous blood donation in total-hip arthroplasty: a cost-effectiveness analysis. Arch Pathol Lab Med 1994;118:465-70.
26. Birkmeyer JD, Goodnough LT, AuBuchon JP, Noordsij PG, Littenberg B. The cost-effectiveness of preoperative autologous blood donation for total hip and knee replacement. Transfusion 1993;33:544-51.
27. Carson JL, Russell LB, Targain MI, Sonnenberg FA, Duff AE, Bauer S. The risks of blood transfusion: the relative influence of acquired immunodeficiency syndrome and non-A, non-B hepatitis. Am J Med 1992;92: 45-52.
28. Whelton MJ. Transfusion-related hepatitis. Q J Med 1994;87:589-91.
29. Andrulis D, Weslowski V, Hintz E, Spolarich AW. Comparisons of hospital care for patients with AIDS and other HIV-related conditions. JAMA 1992;267:2482-6.
30. Eisenstaedt RS, Getzen TE. Screening blood donors for human immunodeficiency virus antibody: cost-benefit analysis. Am J Public Health 1988;78:450-5.
31. Hiatt RA, Quesenberry CP, Selby JV, Fireman BH, Knight A. The cost of acquired immunodeficiency syndrome in northern California. Arch Intern Med 1990;150:833-8.
32. Hicks RA, Cullen JW, Jackson MA, Burry VF. Hepatitis B virus vaccine: cost-benefit analysis. Clin Pediatr 1989;28:359-65.
33. Krahn M, Detsky A. Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis. Med Decis Making 1993;13:4-20.
34. Koretz R. Universal prenatal hepatitis B testing: is it cost-effective? Obstet Gynecol 1989;74:808-14.
35. Dodd RY. The risk of transfusion-transmitted infection. N Engl J Med 1992;327:419-21.
36. Donahue JG, Mung A, Ness PM, Brown DE Jr, Yawn DH, McAllister HA Jr, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992;327:369-73.
37. Cumming PD, Wallace EL, Schorr JB, Dodd RY. Exposure of patients to human immunodeficiency virus through the transfusion of blood components that test antibody-negative. N Engl J Med 1989;321:947-52.
38. Ward JW, Bush TJ, Perkins HA, Lieb LE, Allen JR, Goldfinger D, et al. The natural history of transfusion-associated infection with human immunodeficiency virus: factors influencing the rate of progression to disease. N Engl J Med 1989;321:947-52.
39. Nelson KE, Donahue JG, Muñoz A, Cohen ND, Ness PM, Teague A, et al. Transmission of retroviruses from seronegative donors by transfusion during cardiac surgery: a multicenter study of HIV-1 and HTLV-I/II infections. Ann Intern Med 1992;117:554-9.
40. Centers for Disease Control and Prevention, USPHS Working Group. Guidelines for counseling persons infected with human T-lymphotrophic virus type I (HTLV-I) and type II (HTLV-II). Ann Intern Med 1993;118: 448-54.
41. Ness PM, Shirey RS, Thoman SK, Buck SA. The differentiation of delayed serologic and delayed hemolytic transfusion reactions: incidence, long-term serologic findings, and clinical significance. Transfusion 1990;30:688-93.
42. Linden JV. The risk of ABO-incompatible mistransfusion (abstract). Transfusion 1991;31:47S.
43. Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 1990;30:583-90.
44. Gitnick G. Hepatitis 1990. Scand J Gastroenterol Suppl 1990;175:113-7.
45. Wang JT, Wang TH, Lin JT, Sheu JC, Sung JL, Chen DS. Hepatitis C virus in a prospective study of posttransfusion non-A, non-B hepatitis in Taiwan. J Med Virol 1990;32:83-6.
46. Ulich TR, Anders K, Layfield L, Cheng L, Lewin KJ. Chronic active hepatitis of hepatitis B and non-A, non-B etiology: immunohistochemical localization of hepatitis B core antigen in a series of needle biopsies. Arch Pathol Lab Med 1985;109:403-7.
47. Erslev AJ. Erythropoietin. N Engl J Med 1991;324:1339-44.
48. Eguchi K. Management of chemotherapy-induced anemia. Curr Opin Oncol 1995;7:316-9.
49. Denton TA, Diamond GA, Matloff JM, Gray RJ. Anemia therapy: individual benefit and societal cost. Semin Oncol 1994;21(suppl 3):29-35.
50. Sheingold SH, Churchill DN, Muirhead N, Laupacis A. Recombinant human erythropoietin: factors to consider in cost-benefit analysis. Am J Kidney Dis 1991;17:86-92.
51. Henry DH. Recombinant human erythropoietin for the treatment of anemia in patients with advanced cancer. Semin Hematol 1993;30(suppl 6):12-6.
52. Doweiko JP, Goldberg MA. Erythropoietin therapy in cancer patients. Oncology 1991;5(8):31-7.
53. Mol EM, Egberts TCG. Prophylaxis for venous thromboembolism in hip fracture surgery: total costs and cost effectiveness in the Netherlands. PharmacoEconomics 1994;5:48-55.
54. Whittington R, Barradell LB, Benfield P. Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life. PharmacoEconomics 1993;3:45-82.
55. Package insert. Procrit (recombinant human erythropoietin). Raritan, NJ: Ortho Biotech, 1995.
56. Finkler SA. The distinction between costs and charges. Ann Intern Med 1982;96:102-9.
57. Hoagland HC. Myelodysplastic (preleukemia) syndromes: the bone marrow factory failure problem. Mayo Clin Proc 1995;70:673-7.
58. Cazzola M, Ponchio L, Beguin Y, Rosti V, Bergamaschi G, Liberate ML, et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a Phase I/II clinical trial. Blood 1992;79:29-37.